Here is the thing most people get wrong about muscle aging: they assume the problem is the muscle.
The evidence says otherwise. In a 12-week resistance training study published in European Geriatric Medicine, researchers followed 126 healthy older adults, ages 60 to 80, through supervised, periodized strength training. Functional performance surged—a standardized mean difference of 0.67, the largest effect in the study. Eighty percent improved on chair-stand time, Timed Up and Go, and walking speed.
Muscle capacity barely moved. Body composition shifted slightly negative.
Functional gains can appear while muscle capacity barely moves—and more than half may still miss a composite responder threshold.
Last week, we covered exercise dosing and the resistance sweet spot. This week, the delta is this: even when exercise works, it doesn't work on the muscle itself the way we think—and 54 percent of those older adults failed to hit a composite responder threshold despite measurable functional gains.
That disconnect—functional improvement without muscle-level change—opens the door to targets that bypass the muscle entirely, or hit it through pathways exercise can't reach.
Start in the gut.
Researchers at National Taiwan University College of Medicine applied low-intensity pulsed ultrasound—LIPUS, a weak acoustic signal at just 0.3 W/cm²—not to the legs of aging mice, but to their abdomens. Twenty minutes daily for eight weeks. The mice were 92 weeks old, equivalent to roughly 23 human years of aging beyond maturity, with visible hair loss and reduced mobility.
The treated mice gained back gastrocnemius muscle weight. Their muscle fibers enlarged. Grip strength in both forelimbs and hind limbs climbed back toward youthful levels. Type I, fatigue-resistant fibers increased relative to type IIa. Atrogin-1, a molecular marker of muscle protein breakdown, dropped significantly.
None of that is the strange part.
The strange part is that the ultrasound never touched the muscle. The researchers found massive deposits of advanced glycation end-products—AGEs, chemically damaged proteins that accumulate with age—and their receptor RAGE in the aged muscle, driving NF-κB and the NLRP3 inflammasome, a chronic inflammatory cascade. LIPUS quieted the entire axis. Senescence markers p53 and p21 fell.
But the most surprising chapter unfolded in fecal samples. 16S ribosomal DNA sequencing revealed that the ultrasound had rebalanced the gut microbiota. The gut–muscle axis, a relatively new focus in aging research, appears to mediate at least some of LIPUS's effects on distant muscle tissue.
This is mouse data. No human trial has yet tested whether abdominal LIPUS can reverse sarcopenia in people. But the technology is already cleared for other clinical uses, and a separate 2025 study in Biogerontology confirmed that LIPUS applied directly to the hindlimbs of aged mice increased gastrocnemius mass and upregulated Fndc5 and Opa1—genes tied to mitochondrial function and muscle regeneration.
Two different targets. Two different mechanisms. Same modality.
Now consider inotodiol, a mycosterol derived from the medicinal mushroom Chaga, published in Signal Transduction and Targeted Therapy. In aged mice and in dexamethasone-induced atrophy models, inotodiol improved muscle mass and function. It enhanced mitochondrial content, elevated oxidative capacity, reduced lipid accumulation.
The mechanism runs through liver X receptor beta, or LXRβ. Inotodiol activates LXRβ, which partners with PPARδ to increase transcription of Sirt3. That in turn activates the LXRβ/SIRT3/PGC-1α pathway—a central regulator of mitochondrial function. Palmitic acid-induced lipotoxicity in muscle cells was attenuated. Lipid metabolism was restored.
This is a mitochondrial story, not an inflammatory one, not a gut-mediated one. It overlaps with where exercise exerts some of its effects—PGC-1α is a well-known exercise-responsive gene—but inotodiol appears to reach it through a route that doesn't require muscle contraction.
The evidence level here is preclinical. Cell culture and mouse models. No human trials.
Calcium handling offers a third angle, and a more complicated one—reported by Lifespan.io from a study comparing 3.7-month-old mice to 33-month-old mice. The old mice had smaller muscles, substantially more CaMKII protein in muscle tissue, and more evidence of CaMKII activity at rest.
CaMKII is a kinase that regulates muscle adaptations to exercise. In young tissue, exercise produces reactive oxygen species that stimulate muscle growth. In aged tissue, calcium ions leak from the sarcoplasmic reticulum, mitochondria uncouple from calcium release units, and oxidative damage accumulates.
The researchers used an adeno-associated virus to force constant CaMKII activity in one tibialis anterior muscle per mouse. Within two months, the targeted muscle shrank and became pound-for-pound weaker. Direct stimulation at multiple frequencies showed it couldn't exert nearly as much force.
Blocking NF-κB while activating CaMKII blunted some effects. The muscles didn't become functionally weaker, but they still lost mass. Nine months later, the mass loss was even more significant.
When the researchers injected naturally aged mice with CN19o, a CaMKII inhibitor, the sum total of gene expression shifted toward a more youthful phenotype. It didn't increase muscle size in 21-month-old mice, but it increased their ability to contract.
The researchers are careful: they did not validate why constant CaMKII activation produces its mitochondrial effects, nor did they fully elucidate the calcium–iron signaling connection. This is a mechanism study, not a therapeutic one. No human data.
Then there is creatine—the most clinically advanced of these targets. A 12-week trial from Texas A&M, published in the Journal of the International Society of Sports Nutrition, enrolled 64 middle-aged and older adults, ages 45 to 65, average BMI around 30. Participants chose whether to exercise, then were randomized to creatine monohydrate—five grams twice daily—or placebo.
Both creatine groups gained lean tissue. Placebo groups showed little change. Even creatine without exercise improved bench-press strength relative to non-exercising placebo.
Body-fat percentage declined by about 3.24 percent with exercise, diet, and creatine, versus 1.87 percent with exercise, diet, and placebo. Leg-press max increased by about 34 percent with exercise plus creatine, versus 18 percent with exercise plus placebo.
The researchers acknowledge a critical limitation: DXA-measured lean tissue is not necessarily all muscle. Creatine increases body water, which inflates lean-mass estimates.
Cognitive analyses mostly showed no significant differences, though a few individual comparisons—like word recognition—favored creatine. The overall cognitive picture was not broadly positive.
The trial was small, and exercise participation was not randomized—only supplement allocation was.
But the signal is there. Creatine, at least in this population, preserved or increased lean mass even without exercise, and amplified gains when combined with it.
What ties these together is the heterogeneity problem. The 12-week resistance training study found that 46 percent of participants qualified as multidomain responders; 54 percent did not. Non-responders still improved functionally, but their profiles were marked by worsening pain and quality of life.
If a substantial fraction of older adults don't respond to exercise at the muscle level—or respond in ways that trade functional gain for pain—then non-exercise targets aren't optional. They're necessary.
LIPUS through the gut. Inotodiol through mitochondria. CaMKII inhibition through calcium handling. Creatine through ATP regeneration and water retention.
Each hits a different node. None has yet been validated in large human trials for sarcopenia. The Nature Reviews Drug Discovery review of sarcopenia therapeutics lists mitochondrial function, autophagy, anabolic signaling, vascularization, inflammageing, and innervation as active targets—but notes there are currently no approved therapies.
That absence is precisely why the heterogeneity matters. Exercise remains the best-supported intervention. But for the half who don't fully respond, and for those who cannot exercise at all, the muscle isn't the only place to look.
The gut is. The mitochondria are. The calcium channels are.
The muscle was never the whole story. Now the science is catching up.